Research


Law Is Code: A Software Engineering Approach to Analyzing the United States Code

with William Li, Pablo Azar, David Larochelle, Phil Hill, Journal of Business & Technology Law 10(2015), 297–374.

View abstract

Reply to “(Im)Possible Frontiers: A Comment”

with Thomas J. Brennan, Critical Finance Review 4(2015), 157–171.

View abstract

Funding Translational Medicine via Public Markets: The Business Development Company

with Sandra M. Forman, Monica Shilling, Grace K. Sweeney, Journal of Investment Management 13(2015), 9–32.

View abstract

Hedge Funds: A Dynamic Industry In Transition

with Mila Getmansky, Peter A. Lee, Annual Review of Financial Economics 7(2015), 483–577.

View abstract

Financing Translation: Analysis of the NCATS Rare-Diseases Portfolio

with David E. Fagnan, N. Nora Yang, John C. McKew, Science Translational Medicine 7(2015), 276ps3.

View abstract

Dealing with Femtorisks in International Relations

with Aaron Benjamin Frank, Margaret Goud Collins, Simon A. Levin, Andrew W. Lo, Joshua Ramo, Ulf Dieckmann, Victor Kremenyukf, Arkady Kryazhimskiy, JoAnne Linnerooth-Bayer, Ben Ramalingam, J. Stapleton Roy, Donald G. Saari, Stefan Thurner, and Detlof von Winterfeldt, Proceedings of the National Academy of Sciences 111(2014), 17356–17362.

View abstract

Hedge Fund Beta Replication: A Five-Year Retrospective

with Peter A. Lee, Journal of Investment Management 12(2014), 5–18

View abstract

Financing Drug Discovery for Orphan Diseases

with David E. Fagnan, Austin A. Gromatzky, Jose-Maria Fernandez, Roger M. Stein, Drug Discovery Today 19 (2014), 533-538

View abstract

Wall Street’s Next Bet: Cures for Rare Diseases

Fortune

View abstract

New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc.

with Sourya V. Naraharisetti, Journal of Investment Management

View abstract

Follow me on © 2017 Andrew W. Lo, MIT Sloan School of Management. All rights reserved.
Design by: Opus Design